Drug
Recombinant Interleukin 21
Recombinant Interleukin 21: highest development phase Phase 2, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| recombinant interleukin-21 NCT00601861 | Phase 2 | Cancer |
Latest
No recent events.
Follow Recombinant Interleukin 21 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.